Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
Binayak Sinha,1 Kalyan Kumar Gangopadhyay,2 Samit Ghosal31Department of Endocrinology, AMRI Hospital, 2Department of Endocrinology, Fortis and Peerless Hospital, 3Nightingale Hospital, Kolkata, IndiaAbstract: Insulin therapy is not without side effects. In patients with complications on complex reg...
Saved in:
| Main Authors: | Sinha B, Gangopadhyay KK, Ghosal S |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2014
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c3cd9b184ab64c96921aa90b80cc1f3b |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
by: Wang F, et al.
Published: (2012) -
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
by: Thuillier P, et al.
Published: (2015) -
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
by: Abe S, et al.
Published: (2011) -
Glargine and degludec: Solution behaviour of higher dose synthetic insulins
by: Gary G. Adams, et al.
Published: (2017) -
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
by: Tarigan TJE, et al.
Published: (2021)